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adults, high intensity and/or prolonged-exercise leads to muscle and 
other tissue-damage causing an increased inflammatory-response, 
involving several types of blood cells and pro-inflammatory cytokines 
[9]. During prolonged-exercise, the pattern of inflammatory-
response is different from the response to other kind of stress (e.g., 
hyperthermia, hemorrhagic-shock). Furthermore, even when same 
cytokines (e.g., interleukin-6, interleukin-10, MCP-1) are activated 
during both exercise and in cancer environment, they may have 
different function and trigger different mechanisms (Table 1). In fact, 
the response to prolonged-exercise is featured by a marked elevation 
in circulating cytokines including interleukin-1 receptor antagonist 
(IL-1ra), interleukin-6 (IL-6), and interleukin-10 (IL-10), which varies 
Introduction
Pancreatic-adenocarcinoma is relatively uncommon [1], but 
has been proven to be an unyielding adversity [2]. Pancreatic-cancer 
accounts only ~3% of all cancer diagnoses and is the fourth cause of 
death for cancer in USA [2,3]. These rates are similar in Italy, where 
pancreatic-cancer accounts only 3% of all cancer diagnoses and is the 
fifth cause of death. This equates to 7% of all cancer deaths [4] with a 
total of ~10,000 lives lost to pancreatic-cancer in 2009 [5].
Exercise has demonstrated efficacy for the management of 
treatment related side effects and for improving quality of life (QOL) 
across common cancers such as breast and prostate-cancer [6]. 
However very little data exists exploring the potential impact of exercise 
in pancreatic-cancer patients despite the need to counteract commonly 
experience adverse effects including significant weight-loss, cancer-
related fatigue, nausea, and psychological distress [2,3,7]. In 2014, a 
study reported a case study involving a 49-yr old man with pancreatic-
cancer [8]. The exercise intervention included twice a week sessions 
of moderate-to-high intensity resistance and aerobic-training for 6 
months. Exercise was well tolerated during adjuvant-chemotherapy for 
pancreatic-cancer and led to a range of improvements for this patient 
including considerably improved QOL.
Currently there are no available data identifying the inflammatory-
response during exercise in pancreatic-cancer patients. In healthy 
Abstract
Background: Pancreatic-adenocarcinoma is relatively uncommon, but has been proven to be an unyielding 
adversity. Although it is known the importance of exercise in improving quality of life in cancer patients, currently there 
are no available data identifying the inflammatory-response during exercise in pancreatic-cancer patients undergoing 
chemotherapy.
Methods: A control-supported case study was performed on a 67 yr old man diagnosed with stage IV pancreatic-
cancer. Two 24-hour non-stop ultra-endurance walking races (24 hr Walk) completed by the patient prior to cancer-
diagnosis (No Chemo, 6 months prior to the diagnosis) and after cancer-diagnosis during chemotherapy (Chemo) were 
compared. Comparison to control-participants without cancer (n=2, Ctrl 1 and Ctrl 2) was also conducted. Throughout 
24 hr Walk blood-samples were collected every 6 hours and analyzed for intereukin-1β (IL-1β), interleukin-1ra (IL-1ra), 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), monochemoattractant 
protein-1 (MCP-1), C-reactive protein (CRP), alanine aminotransferase (ALT), pancreatic amylase (AmylP), and 
albumin. All training performed since the cancer-diagnosis was monitored. 
Results: No adverse events occurred neither during 24 hr walks nor during the training. The number of walk per 
week, distance, and speed diminished following the diagnosis of pancreatic-cancer. Changes in IL-1β, IL-6, IL-8, IL-10, 
TNF-α, MCP-1, ALT, AmylP, and albumin did not differ between No Chemo and Chemo. IL-1ra decreased in No Chemo, 
but increased in Chemo. CRP increased in both No Chemo and Chemo, and in the controls as well. Changes in ALT and 
AmylP in Ctrl 1 and Ctrl 2 differed to both No Chemo and Chemo. 
Conclusions: Understanding the inflammatory-response to exercise in cancer-patients may be useful to design 
and delivery adapted exercise-programs in this growing population. The inflammatory-response, hepatic, and pancreatic 
functionality during prolonged-exercise were not exacerbated by concurrent chemotherapy in a pancreatic-cancer 
patient.
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according to exercise-duration (Table 1) [9]. This is in contrast to the 
level of circulating interleukin-1β (IL-1β) and tumor necrosis factor-α 
(TNF-α), which are commonly blunted or absent [10]. Exercise also 
induces counter-regulation of inflammation through secretion of 
immunosuppressant mediators, such as cortisol and anti-inflammatory 
cytokines. In addition, levels of positive acute-phase response-proteins, 
such as C-reactive protein (CRP), increase during a bout of exercise, 
whereas levels of negative ones, such as albumin and transferrin, 
decrease [11].
In recent literature, it has been reported that IL-1, IL-6, and 
TNF-α promote inflammation-associated carcinogenesis and 
influence chemo-resistance in pancreatic-tumors [12]. Specifically, 
these interleukins induce the activation of several transcription 
factors culminating in the formation of numerous pro-inflammatory 
molecules that recruit and activate various leukocyte populations into 
the tumor microenvironment [12]. These and other inflammatory 
mechanisms contribute to pancreatic-cancer development (Table 
1) [13]. The principal cytokines involved in pancreatic-cancer are:
interleukin-1β, IL-ra, IL-6, interleukin-8 (IL-8), IL-10, monocyte
chemoattractant protein 1 (MCP-1), TNF-α, and CRP. Furthermore
there is increasing evidence that systemic inflammation may mediate
a number of metabolic processes that contribute to cancer-cachexia
[14,15]. A study demonstrated that a proportion of pancreatic-cancer
patients who lose weight have an elevated hepatic acute-phase protein-
response (APPR), which correlates to both increased resting energy
expenditure and duration of survival [14]. The principal regulator of
APPR in human hepatocytes is thought to be IL-6 [14].
Cancer and its treatment impact systemic levels of inflammation, as 
does exercise. Although exercise has been found to effectively improve 
QOL, decrease fatigue levels, and improve physical-functioning, very 
little information is available exploring the inflammatory-response 
of pancreatic-cancer patients to exercise. The duration and intensity 
of exercise influences the inflammatory, but it is unclear if there are 
any interaction effects of prolonged-exercise cancer and its treatment. 
Therefore, the first aim of this study was to investigate whether the 
inflammatory-response to prolonged-exercise, such a 24-hour non-
stop ultra-endurance walking, is impacted by chemotherapy for the 
treatment of pancreatic-cancer.
Materials and Methods
Subjects
Pancreatic-cancer patient: This case study involved an Italian 67-
yr old man (mass 63.5 kg, height 178 cm, BMI 20) with a histological 
diagnosis of pancreatic-cancer. The patient was married, retired 
for 9 yrs, and physically active. Since his retirement, he took part in 
several multi-stage treks, such as Monti Liguri mountain way route 
(400 km) and Via Alpina mountain way route (>1,300 km), and 12-, 
24-, 36-, and 48- hour non-stop ultra-endurance walking events. In 
2013, he undertook one 36-hour non-stop ultra-endurance walking 
in March (Catania, Sicily), and two 48-hour non-stop ultra-endurance 
walking events in May and June (Affi, Veneto, and Barrea, Abruzzo, 
respectively), and the Mons Gibel Tour, a 20-day trekking along Etna’s 
periplo (Sicily), in July (Table 2).
He was diagnosed with a pancreatic-adenocarcinoma in September 
2013 (stage IV; PS 0; 55 mm and 27 mm invasive components in 
pancreas body; liver involvement with multiple invasive components, 
6-month life expectancy). Cancer-diagnosis came when the patient,
after a long summer, fully scheduled with periods of consecutive
walking events noticed he was not re-gaining weight and experienced a 
sudden, strong stomach ache (Table 2).The patient did not have history 
of pancreatitis, diabetes or any other conditions involving pancreas.
At the diagnosis, the cancer was not resectable and the treatment
involved adjuvant-chemotherapy, which commenced one week after
the diagnosis. Each chemotherapy cycle included seventeen days of
therapy, which was administered in a series of nine cycles (Table 2). On 
the first day of each cycle, the patient received a dose of Epirubicine, 62 
mg, and Cisplatinum, 76 mg, given by intra-arterial infusion. On the
second day, the patient received a dose of Gemcitabine, 1,800 mg, given 
by intravenous infusion. From the third day and for the consecutive 14 
days the patient took Capecitabine per os, two pills of 500 mg, twice a
day. Due to low platelet-count the treatment plan was modified from
cycle five as detailed in (Table 2).
Control-subjects: Two men without cancer were monitored 
to provide a control-comparator for the inflammatory-response to 
prolonged-exercise. One control-subject was a 55-yr old man (Ctrl 1, 
mass 89.8 kg, height 180 cm, BMI 28) and the other control-subject was 
Pancreatic cancer During strenous/intense exercise
IL-1β Enhances the adhesion of pancreatic-carcinoma cell lines to the microvascular endothelium ↓ slightly
IL-1ra Inhibits IL-1 release during acute phase inflammatory response ↑Inhibits IL-1β; enhances systemic levels of cortisol
IL-6
 Enables tumor growth and inhibits apoptosis; alters lipid and protein 
metabolisms, inhibits biosynthesis by adipocytes and causes atrophy and 
increased catabolism of muscle protein 
↑ 
 Acting as an energy sensor for mobilizing extra-cellular substrates; inhibits 
TNF-α, and IL-1β; increases IL-1ra and IL-10; maintains high plasmatic levels 
of cortisol. Related to duration of exercise.
IL-8
Promotes angiogenic response in endothelial cells; increases proliferation and 
survival of endothelial and cancer-cells; potentiates cell migration of the tumor 
site
↑ High local expression; would be chemoattraction on neutrophils and 
macrophages; stimulate angiogenesis
IL-10 Pro-inflammatory effect enhancing release of IL-1 and TNF-α ↑  Enhances systemic levels of cortisol
MCP-1 Potent angiogenic factor by recruiting tumor-infiltrating macrophages and subsequently the production of angiogenic growth factors
↑ 
Promotes muscle regeneration and functional recovery through regulation of 
monocyte/macrophage recruitment or activation
TNF-α Enhances tumor growth and metastasis; enhances the adhesion of pancreatic-carcinoma cell lines to the microvascular endothelium
= or ↑/↓ slightly 
Facilitates the migration of immune cells in injured tissue. Results of systemic 
endoxemia induced by decrease in blood flow to the splanchnic bed. 
Related to duration and intensity of exercise.
CRP  Marker for acute chronic inflammation; induced by rise in IL-6 values; exerts inhibitory effects on tumor proliferation; angiogenesis and distant metastasis
↑
Marker of acute phase response
Table 1: Principal cytokines involved in pancreatic-cancer and their different functions during cancer and during excercise.
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in age and BMI, these subjects were chosen, because their experience 
in non-stop ultra-endurance walking is quite similar to the experience 
of our main subject. All procedures were in accordance with the ethical 
a 41-yr old man (Ctrl 2, mass 69.0 kg, height 173 cm, BMI 23). Both 
the control-subjects were healthy, physically active, and experienced in 
this kind of ultra-endurance walking events. Despite of the difference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
03-04/03/2013 
24h non-stop ultra-endurance walking, Catania 
Walking effective time: 22:29 
Walked distance: 130 km 
Pause effective time: 01:41 (4.2%) 
Mean speed: 5.9 ± 0.9 km/h 
May 2013: 48h non-stop ultra-endurance walking, Affi 
June 2013: 36h non-stop ultra-endurance walking, Barrea 
July-August 2013: Mons Gibel multi-stage walking, Etna - Sicily 
04/09/2013 
DIAGNOSIS 
Pancreatic-adenocarcinoma, with metastasis and 
liver involvement, 6-month life expectancy 
12/09/2013 - I CYCLE CHEMOTHERAPY    [62 mg Epirubicine + 76 mg 
Cisplatinum] 
                                                                               [1800 mg Gemcitabine] 
                                                                               [2x 500 mg Capecitabine twice day] 
17/10/2013 - II CYCLE CHEMOTHERAPY   [62 mg Epirubicine + 76 mg 
Cisplatinum] 
                                                                               [1800 mg Gemcitabine] 
                                                                               [2x 500 mg Capecitabine twice day] 
14/11/2013 - III CYCLE CHEMOTHERAPY  [62 mg Epirubicine + 76 mg 
Cisplatinum] 
                                                                               [1800 mg Gemcitabine] 
                                                                               [2x 500 mg Capecitabine twice day] 
12/12/2013 - IV CYCLE CHEMOTHERAPY  [62 mg Epirubicine + 76 mg 
Cisplatinum] 
                                                                               [1800 mg Gemcitabine] 
                                                                               [2x 500 mg Capecitabine twice day] 
14/01/2014 - V CYCLE CHEMOTHERAPY    [60 mg Epirubicine + 70 mg 
Cisplatinum] 
 
T/w: 5 
Mean speed: 5.0  km/h              
Walked distance: 272  
km          
                 PRE      POST 
WBC         5.8          2.26 
HBG         13.4        11.5 
PLT           123          97 
T/w: 2 
Mean speed: 4.4  km/h 
Walked distance: 184  
km 
                 PRE      POST 
WBC         5.7          3.1 
HBG         11.2        11.8 
PLT           125          92 
T/w: 1 
Mean speed:  4.8  km/h 
Walked distance: 31  km 
                 PRE      POST 
WBC         6.3         1.86 
HBG         11.6        11.3 
PLT           168          84 
T/w: 1                       
Mean speed:  4.6  km/h 
Walked distance: 13  km 
N/A 
T/w: 2 
Mean speed: 5.7  km/h 
Walked distance: 78  km 
                 PRE      POST 
WBC         3.5          3.6 
HBG         10.4        10.8 
PLT           68           108 
T/w: 1 
Mean speed:  4.8  km/h 
Walked Distance: 58  km 
                 PRE       POST 
WBC         N/A         3.1 
HBG          N/A       10.3 
PLT           N/A         94 
04-05/03/2014 
24h non-stop ultra-endurance walking 
Walking effective time: 20:53  
Walked distance: 113 km 
Pause effective time: 01:41 (5.8%) 
Mean speed: 5.5 ± 0.7 km/h 
24/04/2014 -IIX CYCLE CHEMOTHERAPY  [60 mg Epirubicine + 70 mg 
Cisplatinum] 
                                                               [900 mg Gemcitabine] 
 
29/05/2014 -IX CYCLE CHEMOTHERAPY   [50 mg Epirubicine + 60 mg 
Cisplatinum] 
                                                              [900 mg Gemcitabine] 
 
T/w: 1 
Mean speed: 5.3  km/h 
Walked distance: 15  km 
                 PRE       POST 
WBC         3.2          1.56 
HBG         11           10.1 
PLT           115          54 
T/w: 2 
Mean speed: 6.5  km/h 
Walked distance: 39  km 
                 PRE       POST 
WBC        2.2           1.6 
HBG         10.2         8.3 
PLT           119          62 
08/09/2014 - DEATH 
25/03/2014 -VII CYCLE CHEMOTHERAPY  [60 mg Epirubicine + 70 mg 
Cisplatinum] 
                                                                                [900 mg Gemcitabine] 
                                                                                [500 mg Capecitabine twice day] 
13/02/2014 - VI CYCLE CHEMOTHERAPY  [60 mg Epirubicine + 70 mg 
Cisplatinum] 
 
Table 2: Time line of the patient history from the 24-hour non-stop ultra endurance walking and time course of cancer-treatment from the diagnosis to the completion 
of 9 cycles of chemotherapy. Amount of physical activity between the treatments, and value of white blood cells (WBC), hemoglobin (HBG), and platelets (PLT) pre- 
and post- treatment are presented in conjunction with treatment history. N/A: not available data. T/w: times a week.
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standards of the institutional research committee and with the 1964 
Helsinki declaration and its later amendments. Informed consent was 
obtained from all individual participants included in the study.
24 hr non-stop ultra-endurance walking
Chemo: 24 hr walk completed during chemotherapy for the 
treatment of pancreatic cancer occurred on 4th and 5th March 2014 
(Cogorno, Italy). 24 hr walk occurred twenty days after the sixth 
chemotherapy cycle, when the patient did not take neither Gemcitabine 
nor Capecitabine (Table 2).
No chemo: In order to make the study as much complete as 
possible we evaluated further inflammation, hepatic, and pancreatic 
functionality data of the pancreatic-cancer patient during a comparator 
event prior to cancer-diagnosis and treatment. The data were collected 
during a previous 24 hr walk in March 2013 (Catania, Italy). Clearly 
this comparison is limited by the fact that the events occurred 1 year 
apart. However, the similarity of the prolonged-exercise condition 
conducted before and after pancreatic-cancer diagnosis and treatment 
provides a highly valuable comparator condition for this case study.
Controls: Ctrl 1 was monitored during a 24 hr walk in January 
2014 (Verona, Italy). Ctrl 2 was monitored during a 24 hr walk in 
March 2013 (Catania, Italy).
Home-based walk training
The patient did not stop to perform his habitual physical activity 
(PA) after the cancer-diagnosis. A GPS-receiver (Dakota 20, Garmin, 
Olathe, USA) was used to monitor his training-program prior to 24 hr 
walk. The average speed (km/h) and total distance walked (km) was 
tracked for all walks performed. There was no prescribed exercise-
schedule, the participant just completed his habitual walking-activity. 
He had been walking at least once a week for some hours (depending 
on both his perceived physical effort and the weather conditions) prior 
to the cancer-diagnosis. Additionally, white blood cells, platelets (PLT), 
and hemoglobin concentration were measured immediately before, 
and 10 days after, the initiation of each chemotherapy cycle (Table 2).
Data collection and analysis
The data collection and analyses technique was consistent across all 
prolonged-exercise events evaluated in this study. All the assessments 
were conducted one hour before the event start and every 6 hours ( ± 
30 minutes) during the event. Total distance walked (km) and walking 
speed (km/h) were monitored throughout the entire event using a 
GPS-receiver (Dakota 20, Garmin, Olathe, USA).
Blood-samples (20 ml) drawn from the median anterobrachial 
vein were collected as each assessment and immediately transported 
to the laboratory for analysis. The plasma-samples were separated with 
standard centrifugation, according to manufacturer’s instructions (i.e., 
1,300 g for 15 min, at room temperature). The plasma of Ctrl 2 subject 
was collected in Catania and sent later to the analysis laboratory of 
Verona to be processed together with the other samples by the same 
person. Concentration of IL-1β, IL-1ra, IL-6, IL-8, IL-10, MCP-1, 
and TNF-α were determined by means of the commercially available 
MILLIPLEX multi-analyte panel (Merck Millipore, Darmstadt, 
Germany) following the manufacturer’s recommendation. CRP was 
measured on a Cobas c501 (Roche Diagnostics GmbH, Mannheim, 
Germany), using proprietary reagents. As the patient had pancreatic-
metastasis with liver involvement, pancreatic and hepatic functionality 
were measured in addition to the inflammatory markers. Specifically 
alanine aminotransferase (ALT), pancreatic amylase (AmylP), and 
albumin were measured on a Cobas c501.
Statistical Analyses
Pearson’s correlation analysis has been performed in order to reveal 
the direction and level of significance of the observed results. Statistical 
analysis was performed with SPSS version 21 for Windows 8.1.
Results
Home-based walk training
 No adverse events occurred during any of the training walks. Since 
the diagnosis, the subject completed 61 walks in a period of 8 months. 
In this period, he covered a total distance of 701 km. At the beginning 
of chemotherapy, he walked almost every day. As treatment progressed 
there were months during which he walked less than once a week (Table 
2). Reasons for avoiding walks were chemotherapy-related side effects 
such as fatigue or a poor PLT level, and/or bad weather condition.
Chemo
No adverse events occurred during Chemo. Reasons for breaks 
included metabolic measurements, glycaemia and ketones tests, food 
intake, and toilet breaks. He walked a total of 113 km (Table 2).
No Chemo
 No adverse events occurred during No Chemo. He walked a total 
of 123 km. Reasons for breaks included metabolic measurements, food 
intake, and toilet breaks.
Control
Ctrl 1 covered 107 km and Ctrl 2 covered 150 km.
Inflammation, pancreatic, and hepatic functionality markers
The inflammatory-response during the prolonged-exercise events 
is presented in Table 3, Figures 1 and 2. IL-1β (Figure 1, panel B) 
and TNF-α remained stable throughout 24 hr walk in No Chemo. 
Concentrations of these two markers at baseline and throughout the 
whole walk were higher in No Chemo. In comparison, in Ctrl 1 and 
Ctrl 2 IL-1β remained stable, while TNF-α tended to decrease with the 
time by ~1.7 fold. IL-1ra tended to decrease slightly over the time for 
No Chemo, meanwhile it increased in Chemo by 2.3 fold, and in Ctrl 
1 and Ctrl 2 by ~18.4 fold. Starting from different baseline values, IL-6 
increased in all the subjects: by 6.7 fold in No Chemo, by 7.7 fold in 
Chemo, and by ~26.6 fold in Ctrl 1 and Ctrl 2. IL-8 increased in all 
subjects: by 1.7 fold in No Chemo, by 0.2 fold in Chemo, and by ~1.6 
fold in Ctrl 1 and Ctrl 2. IL-10 increased only in No Chemo and Chemo, 
in both cases by 2 fold. Differently from No Chemo and Chemo, in Ctrl 
1 and Ctrl 2 IL-10 did not increase over the time (Figure 1, panel A). 
MCP-1 increased until the 18th hour, and then it decreased slightly in 
all the subjects. CRP increased in all the subjects: by 6.6 fold in No 
Chemo, by 4.2 fold in Chemo, and by ~21.5 fold in Ctrl 1 and Ctrl 2.
Albumin remained stable in all subjects during the whole walk. 
We have to point out that albumin in both No Chemo and Chemo 
was lower than in Ctrl 1 and Ctrl 2. Although starting from different 
baseline values, ALT remained stable in No Chemo and Chemo, 
while increased by ~12 fold in Ctrl 1 and Ctrl 2 (Figure 2, panel A).. 
Furthermore, starting from different baseline values, AmylP remained 
stable in both No Chemo and Chemo, while decreased by ~5.2 fold in 
Ctrl 1 and Ctrl 2 (Figure 2, panel B)
Discussion
In this control-supported case study, we report novel findings 
regarding the inflammatory-response, pancreatic, and hepatic 
Citation: Pedrinolla A, Ardigò LP, Salvagno GL, Volti GL, Caveggion E, et al. (2016) Inflammatory Response to Exercise in a Pancreatic-cancer 
Patient: a Case Report. Pancreat Disord Ther 6: 176. doi: 10.4172/2165-7092.1000176
Page 5 of 8
Volume 6 • Issue 4 • 1000176
Pancreat Disord Ther, an open access journal
ISSN: 2165-7092
functionality during prolonged-exercise in a pancreatic-cancer patient 
prior to cancer-diagnosis and after diagnosis during chemotherapy. 
Additionally, we compared the inflammatory-response of the 
pancreatic-cancer patient with two healthy control-subjects (with 
pooled-data from two different events). To our knowledge, there are no 
previous evaluations of the inflammatory-response monitored during 
an exercise in a pancreatic-cancer patient undergoing treatments that 
impact systemic inflammation. The majority of studies investigating 
No chemo Chemo Ctrl 1 Ctrl 2
 Basal Peak Mean (SD)  Basal Peak Mean (SD)  Basal Peak Mean (SD)  Basal Peak Mean (SD)  
IL-1β
pg/ml 3.5 4.4 3.8 ± 0.4 = NSC 2.9  2.9  2.9 ± 0 = NSC  2.9  2.9  2.9 ± 0 = NSC 2.9  2.9  2.9 ± 0 = NSC
IL-lra 
pg/ml 25.8 28.6 26.9 ± 2.4 ↓ NSC  18.9  28.6  19.8 ± 5.8 ↓ NSC  4.9  142.2  102.1 ± 56 ↑ NSC  4.9  7.3  4.5 ± 1.9 ↑ .71 (.40)
IL-6 
pg/ml 7.2 40.5 22.3 ± 12.4 ↑ .75 (.14)  5.3  36.4  22.1 ± 12.9 ↑ .96 (.01)  1.24  25.2  12.5 ± 10.4 ↑ NSC  1.2  45  20.5 ± 15.9 ↑ NSC
IL-8 
pg/ml 14.7 24.3 18.9 ± 3.4 ↑ .89 (.04)  22.9  30.7  26.2 ± 4.7 ↑ .79 (.12)  10.4  10.4  4.2 ± 3.4 ↓ NSC  10.3  16  12.7 ± 2.6 ↓ NSC
IL-10 pg/
ml 10.9 20.9 14.6 ± 4.0 ↑ .89 (.04)  4.2  7.7  5.8 ± 1.8 ↑ .85 (.06)  3.1  5.2  3.4 ± 0.9 ↑ NSC  3.0  3.0  3.0 ± 0.0 = NSC
TNF-a 
pg/ml 10.2 10.9 10.4 ± 0.4 = NSC  6.47  8.8  7.3 ± 1.0  = .85 (.06)  21.8  21.8  12.7 ± 5.1 ↓ NSC  21.8  21.8 18.6 ± 2.3 ↓ .89 (.45)
MCP-1 
pg/ml 1565 3433 2441 ± 715 ↑ NSC  1848  2324  2111 ± 200 ↑ .83 (.07) 1280 2668  1840 ± 636 ↑ NSC  1280  2483  1745 ± 576 ↑ NSC
Albumin 
g/L 39.7 40.6 38.8 ± 0.6 = NSC  1741.2  41.2  38.8 ± 1.2 = NSC 47.3  50.2  47.8 ± 1.5
↑ .94 
(.09)  47.3  48.0  46.4 ± 1.6 ↑ .91 (.47)
ALT 
U/L 4 5 3.8 ± 0.8 = NSC  6  6  4.8 ± 0.8  = -.75 (.14)   16  10.4 ± 5.8 ↑ NSC   9  6.8 ± 3.3 ↑ NSC
AmiiP 
U/L 17 17 15.6 ± 1.1 = -.95(.01)  10  10  8.6 ± 1.1  = -.83 (.08)  195  195  61 ± 74.9 ↓ NSC  195  195  100.8 ± 62.7 ↓ NSC
CRP 
mg/L 3.6 21.8 8.38 ± 7.84 ↑ .85 (.06)  3.4  13.1  6.5 ± 4.2 ↑ .78 (.12)  1.2  23.3  7.4 ± 9.3 = NSC  1.2  28.3  10.4 ± 11.8 = NSC
During 24-hours non-stop ultra endurance walking in a patient with pancreatic-cancer (No Chemo); the same patient undergoing chemotherapy (Chemo); and two healthy 
control-subjects (Ctrl 1 and Ctrl 2). For every substance/condition and/or subject: basal value, peak value, mean and standard deviation, strong Pearson’s correlation (>.70) 
with p value or no strong Pearson’s correlation (NSC). For cytokines acronyms read text, for patterns as in Table 1.
Table 3: Cytokines, hepatic and pancreatic function markers variation.
No Chemo
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Figure 1: Inflammation markers: changes in interleukin 10 (IL-10, panel A); interleukin 1β (IL-1 β, panel B), 1 during 24-hour ultraendurance walking in a pancreatic-
cancer patient (No Chemo, ●), the same patient undergoing chemotherapy (Chemo, ○), and two control-subjects (Ctrl 1, ▲; and Ctrl 2, Δ).
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the impact of ultra-endurance exercise on biochemical variables have 
focused mainly on experienced healthy-athlete [9-11,16-21].
Through the monitoring of self-administered training conducted 
by the patient following the cancer-diagnosis, there is evidence that 
long-distance walk training was relatively well tolerated. It is clear that 
the development of pancreatic-cancer and the resulting administration 
of chemotherapy influenced the quantity (times/week) and quality 
(covered distance) of training achievable (Table 2). Our observation 
is confirmed by recent evidence suggesting that cancer-type, disease 
stage, and treatments may moderate the exercise-response [3]. 
Therefore, considering the influence of chemotherapy on exercise-
response becomes necessary for professionals when planning exercise 
intervention for cancer-patients.
Many baseline inflammatory, hepatic, and pancreatic functionality 
markers did not differ considerably between No Chemo, Chemo, and 
Ctrl 1 and Ctrl 2. However, the inflammatory-response, hepatic, and 
pancreatic functionality throughout 24 hr walk were, for the most 
part, not considerably exacerbated by concurrent chemotherapy in a 
pancreatic-cancer patient (Table 3). There were some differences in 
the response of various variables throughout 24 hr walk highlighting 
the impact of chemotherapy on the systemic inflammatory-response 
of our subject [16]. This is supported by the fact that the inflammation 
response of Chemo was more similar to Ctrl 1 and Ctrl 2 than to No 
Chemo (Figure 1), but also because cytokines were much lower in 
Chemo than in No Chemo (Table 3). This is hypothesized to be due to 
the anti-angiogenesis effect of chemotherapy [22].
While there are no previous studies focused on the inflammatory-
response in pancreatic-cancer during exercise or prolonged-exercise to 
compare our results with, these observations are partially confirmed 
by several studies focused on healthy-subjects. A study investigated 
9 well-trained male endurance-athletes during a 24-hour ultra-
endurance exercise bout (including running, cycling, and kayaking) 
[19]. In these athletes IL-1β and TNF-α did not change, but IL-6, IL-8, 
and CRP increased significantly between pre- and post-exercise [19]. 
Furthermore, another study considered blood-samples from 15 male 
athletes, who finished a 246 km ultra-distance race in less than 36 hours, 
and observed IL-6 and CRP to dramatically increase after the race 
[11]. Further researchers investigated a comparable series of cytokines 
as assessed in the current study in 20 athletes immediately after an 
Ironman triathlon-competition [20]. No changes were observed in 
IL-1β and TNF-α while a range of other inflammatory markers had 
increased significantly at the end of the race (IL-1ra, IL-6, IL-8, IL-10, 
MCP-1, and CRP [20].
In our study the observed pattern of cytokines release during 
prolonged-exercise in Chemo, and Ctrl 1 and Ctrl 2 might reflect a 
partial suppression of pro-inflammatory response, rather than an anti-
inflammatory response. This is highlighted by the non-change of IL-
1β and TNF-α, which would be elevated in the case of an endotoxic-
response [10]. Moreover, IL-6 is most often classified as an anti-
inflammatory cytokine released during exercise, because it seems to be 
triggered by muscle-damage, adrenaline, and energy-imbalance [10]. 
Indeed, IL-6 reacts to the drop in glycogen-storage during conditions 
of continued metabolic energy demands, as for example during a 24 hr 
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Figure 2: Epatic and pancreatic function markers: changes alanine transaminase (ALT, panel A), and pancreatic amilase (panel B) 5 during 24-hour ultra endurance 
walking in a pancreatic-cancer patient (symbols as in Figure 2).
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walk [10]. Furthermore, exercise-induced increase in IL-6 is commonly 
followed by increased concentration of other anti-inflammatory 
cytokines such as IL-1ra. Exercise-related IL-6 would suppress TNF-α 
release [23]. Furthermore, the elevation of IL-8, MCP-1 and CRP in 
our subject may reflect the muscle inflammatory reaction possibly 
related to muscle degenerative events, rather than a cancer-related pro-
inflammatory reaction [20].
It is well established that several cytokines have different roles in 
pancreatic-cancer and during prolonged-exercise (Table 1). IL-10 was 
expected to increase in both No Chemo and Chemo. But we found an 
increase in IL-10 only in Chemo. This might be due to the different role 
of this cytokine in different situations. In fact in a cancer-environment, 
IL-10 would act like anti-apoptotic and tumor-growth factor [24], but 
during exercise it would act like anti-inflammatory cytokine, increasing 
the cortisol-level and inhibiting TNF-α. Furthermore, in Chemo IL-1ra 
level did not increase. The high level of IL-1ra at the baseline in No 
Chemo would reflect a great inflammation caused by infection, tissue 
injury, or disease. Meanwhile, trend of IL-1ra in No Chemo at baseline 
and over 24 hr walk would be explained by the acute-phase protein 
role of this cytokine in cancer [25]. Consequently, we suppose that 
during No Chemo the anti-inflammatory response to the exercise was 
overtaken by pro-inflammatory response to pancreatic-cancer, since it 
was not yet weakened by chemotherapy.
Albumin is involved in protein-synthesis by the liver. Although 
No Chemo and Chemo presented very low albumin-level, it remained 
almost unchanged throughout the duration of 24 hr walk. Even in Ctrl 
1 and Ctrl 2, albumin levels did not change significantly during 24 hr 
walk. ALT (another enzyme involved in hepatobiliary functionality) 
remained almost unchanged in both No Chemo and Chemo, but 
increased significantly in Ctrl 1 and Ctrl 2. Our results are partially 
supported by previous studies. A study investigated biochemical and 
hematological changes in a 61-yr old healthy man before and after a 
120-km swim in open-water [17]. Albumin did not change between 
pre- and post- swimming, while ALT increased by 4.5 fold. Furthermore 
another study considered blood-samples of 11 ultra-marathon 
runners, who ran at least 100 km in 24 hours [21]. Albumin values 
remained unchanged in both these studies, while ALT increased from 
35.1 to 118.4 U/L (3.4 fold) between pre- and post-running. However, 
although Ctrl 1 and Ctrl 2 ALT increased by 12 fold, its highest level 
was 12 U/L, a very low value compared with values recorded by a 
previous study [21]. Consequently, the obtained results lead us to 
hypothesize that prolonged-exercise such as a 24 hr walk does not 
provide enough stimulus to significantly stress hepatic functionality in 
pancreatic-cancer patients or healthy-subjects. Indeed, even if albumin 
and ALT for the patient were consistently lower than those observed in 
the control-subjects, these variables were not exacerbated during 24 hr 
walk. Despite starting from different levels, AmylP (enzyme involved 
in pancreatic functionality) remained almost unchanged in No Chemo 
and Chemo, but decreased dramatically in the first 6 hours in Ctrl 1 
and Ctrl 2. We hypothesize that the large AmylP at the beginning of the 
walk in Ctrl 1 and Ctrl 2 was due to the fact that they were not fasting 
prior to this blood-sample collection-point. However, although AmylP 
in No Chemo and Chemo was lower than in Ctrl 1 and Ctrl 2, it did not 
get worse throughout 24 hr walk.
There are several limitations within this study. First of all we have 
only one pancreatic-cancer patient, who may represent an extreme 
outlier, so the results could refer mainly to the specific response 
to exercise of this person and may not be generalizable to other 
pancreatic-cancer patients. Control-subjects were younger than 
the pancreatic-cancer patient and they have different BMI, so the 
inflammation response might be influenced by this difference in age 
and fat-distribution. Furthermore, we decided to add control-subjects 
prospectively using data previously collected. Another limitation is that 
we conducted inflammatory response analysis only in plasma, without 
considering pro-inflammatory cytokine messenger RNA, which may 
limit the interpretation of the results. Despite these limitations, this 
case study provides the first examination of the inflammatory-response 
of prolonged-exercise in a cancer-patient. While the design is limited 
to a case study, it is strengthened by comparisons between prolonged-
exercise events conducted prior to and during chemotherapy as well as 
with control-subjects without cancer.
Conclusion
This is the first study focused on the inflammation response to 
exercise of a pancreatic-cancer patient. Ultra-endurance non-stop 
walking was associated with a change in inflammatory-response in a 
pancreatic-cancer patient chemotherapy-free and with chemotherapy, 
as well as in healthy-subjects. Nevertheless, even if an ultra-endurance 
non-stop event was characterized by a moderate intensity, this was not 
enough to trigger a pro-inflammation response when the pancreatic 
cancer patient was with chemotherapy. In addition, although the cancer 
had already compromised the pancreatic and hepatic functionalities of 
the pancreatic cancer patient, prolonged exercise was not so intense 
stimulus to significantly exacerbate systemic inflammation. Therefore, 
our results highlight the possibility for pancreatic cancer patients 
undergoing chemotherapy to make moderate exercise, even for 
prolonged time, without encountering negative side effects and without 
triggering a pro-inflammatory response. Further studies are needed 
in order to understand the mechanism of inflammation response to 
regular exercise in cancer patients undergoing chemotherapy.
Consent
Written informed consent was obtained from the patient’s wife and 
from both control subjects for publication of this case report. A copy 
of the written consent is available for review by Editor of this journal. 
Acknowledgements
This manuscript is dedicated to the memory of the subject, M. S., who, in 
the meanwhile, has passed away due to his disease. M. S. will remain forever an 
example of active person and keen collaborator in many research projects.
References
1. Epidemiology and End Results Program (2015) The SEER register Surveillance. 
National cancer Institute. 
2. Oberstein PE, Olive KP (2013) Pancreatic cancer: why is it so hard to treat? 
Therap Adv Gastroenterol 6: 321-337. 
3. Courneya KS, Rogers LQ, Campbell KL, Vallance JK, Friedenreich CM (2015) 
Top 10 research questions related to physical activity and cancer survivorship. 
Res Q Exerc Sport 86: 107-116. 
4. Numico G (2015) Associazione Italiana Registro Tumori: the AIRTUM register 
3: 4-5. 
5. Cutillo A (2015) Household consumption expenditure. Istat.it 2: 19-25. 
6. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvafo DA, 
et al. (2010) American College of Sports Medicine roundtable on exercise 
guidelines for cancer survivors. Med Sci Sports Exerc 42: 1409-1426. 
7. Pedersen BK, Bruunsgaard H, Ostrowski K, Krabbe K, Hansen H, et al. (2000) 
Cytokines in aging and exercise. J Sports Med 21 Suppl 1: S4-9. 
8. Cormie P, Spry N, Jasas K, Johansson M, Yusoff IF, et al. (2014) Exercise 
as medicine in the management of pancreatic cancer: a case study. Med Sci 
Sports Exerc 46: 664-670. 
9. Reihmane D, Jurka A, Tretjakovs P, Dela F (2013) Increase in IL-6, TNF-Î±, and 
Citation: Pedrinolla A, Ardigò LP, Salvagno GL, Volti GL, Caveggion E, et al. (2016) Inflammatory Response to Exercise in a Pancreatic-cancer 
Patient: a Case Report. Pancreat Disord Ther 6: 176. doi: 10.4172/2165-7092.1000176
Page 8 of 8
Volume 6 • Issue 4 • 1000176
Pancreat Disord Ther, an open access journal
ISSN: 2165-7092
MMP-9, but not sICAM-1, concentrations depends on exercise duration. Eur J 
Appl Physiol 113: 851-858. 
10. Welc SS, Clanton TL (2013) The regulation of interleukin-6 implicates skeletal
muscle as an integrative stress sensor and endocrine organ. Exp Physiol 98: 
359-371.
11. Margeli A, Skenderi K, Tsironi M, Hantzi E, Matalas AL, et al. (2005) Dramatic
elevations of interleukin-6 and acute-phase reactants in athletes participating 
in the ultradistance foot race spartathlon: severe systemic inflammation and 
lipid and lipoprotein changes in protracted exercise. J Clin Endocrinol Metab 
90: 3914-3918. 
12. Schmieder A, Multhoff G, Radons J (2012) Interleukin-33 acts as a pro-
inflammatory cytokine and modulates its receptor gene expression in highly
metastatic human pancreatic carcinoma cells. Cytokine 60: 514-521. 
13. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, et al. (2004) Inflammatory 
mechanisms contributing to pancreatic cancer development. Ann Surg 239: 
763-769. 
14. Moses AG, Maingay J, Sangster K, Fearon KC, Ros JA, et al. (2009) Pro-
inflammatory cytokine release by peripheral blood mononuclear cells from 
patients with advanced pancreatic cancer: relationship to acute phase response 
and survival. Onc Rep 21: 1091-1095. 
15. Deans C, Wigmore SJ (2005) Systemic inflammation, cachexia and prognosis
in patients with cancer. Curr Opin Clin Nutr Metab Care 8: 265-269. 
16. Zhou JX, Hong GB, Xu LY, Xu LF, Chen YT, et al. (2004) Efficacy of selective 
continuous transarterial infusion chemotherapy on advanced pancreatic
cancer. Ai Zheng 23: 1677-1680. 
17. Drygas W, Rebowska E, Stepien E, Golanski J, Kwasniewska M (2014) 
Biochemical and hematological changes following the 120-km open-water
marathon swim. J Sports Sci Med 13: 632-637. 
18. Jee H, Jin Y (2012) Effects of prolonged endurance exercise on vascular
endothelial and inflammation markers. J Sports Sci Med 11: 719-726.
19. Marklund P, Mattsson CM, Larsson BW, Ponsot E, Lindvall B, et al. (2013) 
Extensive inflammatory cell infiltration in human skeletal muscle in response to
an ultra endurance exercise bout in experience athletes. J Appl Physiol (1985) 
114: 66-72. 
20. Menicucci D, Piarulli A, Mastorci F, Sebastiani L, Laurino M, et al. (2013) 
Interactions between immune, stress-related hormonal and cardiovascular
systems following strenuous physical exercise. Arch Ital Biol 151: 126-136. 
21. Wu HJ, Chen KT, Shee BW, Chang HC, Huang YJ, et al. (2004) Effects of
24 hr ultra-marathon on biochemical and hematological parameters. World J
Gastroenterol 10: 2711-2714. 
22. Yuan F, Shi H, Ji J, Cai Q, Chen X, et al. (2015) Capacitabine metronomic
chemotherapy inhibits the proliferation of gastric cancer cells through anti-
angiogenesis. Oncol Rep 33: 1753-1762. 
23. Pedersen BK, Akerström TC, Nielsen AR, Fischer CP (2007) Role of myokines
in exercise and metabolism. J Appl Physiol 103: 1093-1098. 
24. Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune
response against cancer: a counterpoint. J Leukoc Biol 78: 1043-1051. 
25. Gabay C, Smith MF, Eidlen D, Arend WP (1997) Interleukin 1 receptor
antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 99: 2930-2940.
